EUCTR2019-003872-37-BE进行中（未招募）1 期
18F-MFBG PET imaging of the norepinephrine transporter in neural crest and neuroendocrine tumors: a phase I PET/CT study
niversity Hospitals Leuven0 个研究点目标入组 10 人开始时间: 2019年11月25日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Age 1 year or older
- •- Signed Informed Consent by the participant (adult) or his/her parents or legal guardian (minors)
- •- Subject is diagnosed with a neural crest tumor or neuroendocrine tumor.
- •- Subject is judged to be in good general condition by the investigator on the basis of medical history, physical examination including vital signs and clinical laboratory tests, besides the diagnosis of a neural crest tumor.
- •- Subject should have a routine clinical 123I-MIBG scintigraphy (planar + SPECT/CT) performed within 6 months prior to the inclusion visit or scheduled within 3 months after the inclusion visit.
- •- Adult female subjects should be post-menopausal or surgically sterile or using effective contraceptive with negative pregnancy test. Minor female participants of childbearing potential that are sexually active should be using effective contraceptive with negative pregnancy test
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 4
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 4
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •- Subject has a previous or ongoing recurrent or chronic disease, other than a neural crest tumor, at high risk to interfere with the evaluation of the trial according to the judgement of the investigator, e.g. known gastro-intestinal, hepatic, renal, cardiovascular, metabolic or hormonal disease, cancer, major neurological or convulsive disorder or any psychiatric disease
- •- Subject is currently, or within two weeks prior to the inclusion visit, a user (including ‘’recreational use’’) of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse
- •- Subject is unable to refrain from smoking more than 10 cigarettes per day during the study
- •- Subject has had exposure to ionizing radiation (> 1 mSv) in other research studies within the last 12 months
- •- Subject suffers from claustrophobia or cannot tolerate confinement during PET/CT scanning procedures
- •- Adult subject cannot lie still for 45 minutes inside the scanner. Minor participant cannot lie still for the duration of at least one whole-body PET/CT, varying from 15 to 30 minutes depending on the length of the child, except for children who will be sedated for one scan
- •- Subject is unwilling to avoid unusual, unaccustomed, or strenuous physical activity (i.e. weight lifting, running, bicycling) from the time of the selection visit until the final safety telephone follow-up interview.
- •- Subject or his/her parents or legal guardion in case of minors, does not understand the study procedure
- •- Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator
- •- Subject is potentially pregnant (serum and urinary hCG test will be performed in women of childbearing potential) or is breast-feeding
- •- Subject has recently (< 30 days or 5 times the plasma half-life of the investigated drug, whichever is longest) participated or is simultaneously participating in another prospective interventional clinical trial
- •- Subject has a history of multiple and/or severe allergies to drugs or food
- •- Subject underwent surgery between the selection and inclusion visit
- •- Adult subject is mentally or legally incapacitated
研究者
相似试验
终止
1 期
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine TumorsNeural Crest TumorNeuroendocrine TumorsNCT04258592Universitaire Ziekenhuizen KU Leuven6
已完成
不适用
PET imaging of the noradrenaline system in different neurodegenerative conditionsneurodegeneratieve aandoeningen (ziekte van Alzheimer)parkinson's disease1008362410028037dementiaNL-OMON51069niversitair Medisch Centrum Groningen50
已完成
不适用
PET imaging of the noradrenaline system in healthy volunteers - a pilot studyNL-OMON48264niversitair Medisch Centrum Groningen4
尚未招募
不适用
PET imaging of the noradrenaline system in healthy volunteers - a pilot studyPilot study: healthy volunteers only.NL-OMON21724niversity Medical Center Groningen4
已完成
早期 1 期
The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose TissueBrown Adipose TissueNCT02038595Yale University10